Business
Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial
Revolution Medicines‘ drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy, the company said Monday.
RevMed said its daily pill, daraxonrasib, met all primary and secondary endpoints in a trial of people whose cancer had already progressed on another treatment. People who took daraxonrasib typically lived for 13.2 months versus 6.7 months for people who took chemotherapy, an increase of 6.5 months, RevMed said in a press release.
“These are dramatic, practice-changing outcomes, and our focus now is moving quickly to bring this potential new treatment option to patients who urgently need new treatment,” RevMed CEO Mark Goldsmith said in an interview.
Goldsmith called the results “unprecedented,” saying no drug has shown an overall survival benefit greater than one year in a Phase 3 trial for pancreatic cancer. The company plans to soon seek Food and Drug Administration approval using a Commissioner’s National Priority Voucher, which grants a review within a matter of months.
RevMed’s pill could bring a new option for people with pancreatic cancer, an aggressive disease that has the lowest five-year survival rate of any major cancer, at 13%. Daraxonrasib broadly targets RAS mutations, which drive tumor growth and are found in about 90% of pancreatic cancer cases.
“These results usher in a new era of RAS-targeted medicines for pancreatic cancer, which has been exclusively treated with cytotoxic intravenous chemotherapy,” Goldsmith said.
For patients, these results are “truly transformational,” said Dr. Shubham Pant, professor of gastrointestinal medical oncology at The University of Texas MD Anderson Cancer Center. Pant said he’s been involved in numerous other studies that have failed, and said previous positive trials extended survival by a few weeks or months.
He’s been involved in trials for RevMed’s daraxonrasib since its early days, and choked up multiple times when describing the results and what they mean for patients, including one who participated in the pivotal trial that Pant had seen just before the interview.
“Today, I’m just, I’m just thankful,” Pant said. “That’s all I can say. And you know, just seeing patients in my clinic today, I’ve got a busy clinic today, and I’m just thankful.”
Daraxonrasib gained more attention last week, when former Republican Sen. Ben Sasse, who was diagnosed with pancreatic cancer late last year and given only months to live, shared his experience taking the drug in an interview with The New York Times. He told the Times that Pant is his doctor.
Sasse said his tumors have shrunk 76% since he started taking the drug, but said it causes “crazy” side effects like a facial rash. His face appeared to be peeling during the interview.
RevMed’s CEO Goldsmith said the company can’t comment on any individual patient, but that a rash is a known side effect and one that’s generally manageable. Pant couldn’t speak to the specifics of Sasse’s case, but said the majority of patients in previous trials of daraxonrasib did experience a rash, though less than 10% of them developed a “dramatic” rash. He said strategies like stopping the drug temporarily or treating with antibiotics can help.
“Honestly, since our journey three years ago, we are getting better at managing these side effects, and I think we keep on getting better at managing side effects,” Pant said.
RevMed on Monday said the drug showed a manageable safety profile in the pivotal study and that no new concerns were observed. The full results will be disclosed at a medical meeting.
The company will seek approval for second-line treatment, or in patients whose cancer has already spread while taking another drug. It’s conducting a Phase 3 trial for newly diagnosed patients.
Daraxonrasib could become a foundation that can be built upon and used in combination with other drugs, said Dr. Andrew Aguirre, associate director of the Hale Family Center for Pancreatic Cancer Research and co-director of the Center for RAS Therapeutics at Dana-Farber Cancer Institute. The results are a “whopping improvement” to be “incredibly excited about as really a foundation,” he said.
“And honestly, it’s reason for optimism for the whole field that targeting RAS in this patient population, and hopefully many other contexts for pancreatic cancer and many other difficult-to-treat diseases is going to have real benefit for patients and be something that we can continue to expand and use in combination,” Aguirre said.
Revolution Medicines shares jumped more than 30% following release of the results Monday. Its stock has climbed about 274% in the last year, in part because it has long been seen as an acquisition target.
Monday’s stock move brings the company’s market value to more than $26 billion. Goldsmith said the company is focused on preparing for approval and launch of its drug, rather than any potential acquisition.
Business
65,000 young people to be offered defence, clean energy and digital training
Around 65,000 young people will be able to train to enter the defence, clean energy, digital and manufacturing industries under the latest round of Government investment into colleges.
The Government will provide £175 million for 19 new Technical Excellence Colleges across the country to deliver training in sectors deemed important for the future of the UK.
Minister for skills Baroness Jacqui Smith said the investment would help build a pipeline of skilled workers for industries key to Britain’s future.
The Government has identified the areas most likely to help grow the economy, Baroness Smith told the Press Association, and said given the war happening in the Middle East, the UK needed to be able to support different ways of getting its energy.
“The Clean Energy (technical excellence colleges) that we’re announcing today will help us to develop that to speed up our shift to clean energy, to protect our energy supply and to help people with their bills,” she said.
“In the area of defence, where, given the instability and some of the new challenges to our defence in the world, and our contribution to that, this Government has pledged a big increase in defence spending that needs to support our armed forces and our capacity, but that spending also needs to deliver quality jobs to the UK defence industry, who will need skilled people in order to be able to deliver it.”
It is estimated nearly 600,000 additional workers will be needed in these key sectors by 2030, the Department for Education said.
If follows the first wave of 10 technical excellence colleges announced last year specialising in construction.
Prime Minister Sir Keir Starmer said: “I want every young person to know there is a clear route into well‑paid work, whatever their background. These colleges put technical skills front and centre, opening up high‑quality jobs in the industries driving Britain’s future.
“We are backing talent across the country, strengthening our workforce and making sure opportunity is built into the system – not left to chance.”
The colleges may spend the funding they receive on specialist equipment, developing new courses, training more specialist staff, and more.
On Monday, Baroness Smith met students and staff at Milton Keynes College, selected as a technical excellence college for digital, where students are already learning about robotics and artificial intelligence (AI).
It comes after the latest figures showed nearly a million (957,000) 16 to 24-year-olds were “Neet” (not in education, employment or training) in October to December 2025.
The high number of young people who were Neet was a “loss of opportunity” and a “loss for the country”, Baroness Smith told PA.
“That’s why we need really high-quality provision for young people between 16 to 19 to be able to access,” she said.
“We need our schools to better identify the young people who are potentially going to become Neet, we need them to take responsibility for making sure that young people have got the places, the college places, the apprenticeships, the jobs to go into.
“And we need brilliant colleges like Milton Keynes, where I am today, to be supported, to be able to provide the opportunities for young people who would otherwise be lost at such a crucial time in their lives and for the future of the skills that we need as a country as well.”
The Government has set a target for two-thirds of young people to be in higher education, higher-level training or doing a gold standard apprenticeship by age 25.
Jawad Al Midani, 21, started studying at Milton Keynes College for a Level 1 course, and has since worked his way up to studying for a Higher National Diploma (HND) in cyber security.
“I feel as soon as I finish my qualifications I’ll be ready to start my career,” he told PA.
Christian Proctor, 18, who is studying for a Higher National Certificate (HNC) in games design and will go on to an HND next year, said he was confident the skills he was learning would equip him for the next step once he finished college.
The 19 new Technical Excellence Colleges are as follows:
Defence
– Blackpool and The Fylde College– City College Plymouth– Lincoln College– RNN Group– Yeovil College
Clean Energy
– Colchester Institute– South Bank Colleges– The City of Liverpool College– The Education Training Collective– University Centre Somerset College Group
Digital and Technologies
– Birmingham Metropolitan College– Capital City College Group– Gloucestershire College– LTE Group– Milton Keynes College
Advanced Manufacturing
– City of Wolverhampton College– New College Durham– Newcastle and Stafford College Group– Weston College of Further and Higher Education
Business
Why retail sales increased last month despite shoppers’ caution amid Iran war
Consumer spending on non-food items remained “tepid” in March as shoppers exercised heightened caution amid ongoing conflict in the Middle East, new figures reveal.
Data from the British Retail Consortium (BRC) and KPMG shows that non-food sales saw a modest 0.9% year-on-year increase last month, falling short of the 12-month average of 1.1%.
This subdued performance was further underscored by online non-food sales, which rose by a mere 0.1%, significantly below the annual average of 1%, indicating a dip in consumer confidence.
While overall UK retail sales climbed by 3.6% compared to a year ago, surpassing the 12-month average of 2.6%, this was largely attributed to an early Easter and inflationary pressures. Food sales experienced an artificial boost, increasing by 6.8%, which skewed the total retail figures.
Demand proved robust for categories such as computers, toys, and homeware. However, the clothing and footwear sectors continued to face challenges. Furthermore, the uncertainty surrounding international travel due to the Middle East situation negatively impacted sales of travel-related goods.
BRC chief executive Helen Dickinson said: “An early Easter provided a much-needed boost to food sales as families came together over the long weekend.
“Retailers hope that the Middle East ceasefire will bring lasting stability, but the outlook remains uncertain.
“Damage to supply chains has already been done, and rising costs – from shipping and fertiliser to insurance and commodities – are piling yet more pressure on to already stretched retailers.
“Government must act decisively and boldly now to curb inflation by delaying domestic policies that would push prices even higher for shoppers.”
Linda Ellett, UK head of consumer, retail and leisure at KPMG, said: “Food and drink continue to drive monthly retail sales growth, with inflation a key factor.
“Non-food sales growth remains tepid, growing at under 1% so far this year, as consumer spending caution is heightened by the current and potential impact of the Middle East conflict.”
Separate figures from Barclays show travel spending declined by 3.3% in March after five years of growth as trips abroad were delayed or swapped for staycations.
Consumer card spending increased 0.9% year on year, down from February’s 1%, the bank’s data shows.
Essential spending returned to growth – up 0.5% – for the first time since July last year as fuel prices surged, while discretionary spending growth slowed to 1.1%, driven by the decline in travel, for the first time since 2021.
However, a survey for Barclays found overall consumer resilience remained strong, with 71% of UK adults feeling confident in their ability to live within their means each month.
In response to uncertainty around the Middle East conflict, 14% said they were delaying major purchases or financial decisions, while the same proportion were building up a savings buffer in case costs rise.
Some 74% anticipate ongoing tensions will continue to affect the cost of living throughout the rest of the year.
Jack Meaning, chief UK economist at Barclays, said: “Shoppers delaying major purchases and building up a savings buffer in response to the shock from the Middle East reinforces our view that activity will be muted in the coming months.
“With an interest rate decision due in less than three weeks’ time, the Bank of England will need to consider how to balance this softening economy with the inflation already taking effect.
“Our modelling suggests this balance is best struck by holding rates, containing the worst of inflation without unduly squeezing consumers.”
Opinium surveyed 2,000 UK adults between March 27-31.
Business
Goldman Sachs tops estimates on record equities trading
Goldman Sachs on Monday posted first-quarter results that topped expectations on record equities trading results and higher-than-expected investment banking revenue.
Here’s what the company reported:
- Earnings: $17.55 per share vs. $16.49 LSEG estimate
- Revenue: $17.23 billion vs. $16.97 billion expected
The bank said profit climbed 19% from the year-earlier quarter to $5.63 billion, or $17.55 per share. Revenue rose 14% to $17.23 billion.
Trading desks across Wall Street were busy at the start of the year as institutional investors set new positions against the churn of artificial intelligence-led disruption in markets. For Goldman, that resulted in its biggest quarter from equities trading, helping propel the overall firm to its second-highest quarterly revenue.
Equities revenue rose 27% to $5.33 billion, or about $420 million more than the StreetAccount estimate, on rising financing activity to hedge fund clients in its prime brokerage business, as well as matching more buyers and sellers in cash equities products.
Investment banking fees climbed 48% to $2.84 billion, about $340 million more than expected, on a surge in advisory revenue from completed mergers transactions. The firm also cited higher revenue in equity and debt underwriting.
But the firm’s fixed income operations didn’t fare as well. Revenue there fell 10% to $4.01 billion, an unusually large miss of $910 million versus the StreetAccount estimate. Goldman cited “significantly lower” revenues in interest rate products, mortgages and credit for the results.
The firm’s asset and wealth management division saw a 10% jump in revenue to $4.08 billion in the quarter. But that was about $140 million below expectations, as higher management fees from rising assets under supervision were partially offset by lower private banking revenues.
Goldman’s provision for credit losses rose nearly 10% from a year earlier to $315 million, or more than double the StreetAccount estimate of $150.4 million, on loan growth and impairments on wholesale loans.
It was the bank’s largest increase in loan loss provisions since 2020, which raises questions as to what Goldman executives see developing in credit markets, Wells Fargo banking analyst Mike Mayo said Monday morning in a note.
Shares of the bank fell almost 2% Monday.
The bank’s results in the quarter were also helped by a lower-than-expected tax rate, compensation ratio and a larger-than-expected stock buyback, Barclays banking analyst Jason Goldberg said in a note.
For Goldman Sachs, which gets most of its revenue from its trading and investment banking franchise, the main question analysts will have is about the impact of the Iran war that started on Feb. 28.
Disruptive events that impact the price of commodities — like the Iran conflict has — can sometimes force corporate clients to the sidelines, which could threaten future capital markets deals like mergers or debt issuance.
Goldman CEO David Solomon referenced rising volatility “amid the broader uncertainty” of the period.
“Goldman Sachs delivered very strong performance for our shareholders this quarter, even as market conditions became more volatile,” Solomon said in the earnings release. “The geopolitical landscape remains very complex – so disciplined risk management must remain core to how we operate.”
Later Monday, Solomon told analysts on a conference call that while the environment for mergers and other deals has been resilient, he was closely monitoring how the war in the Middle East was developing.
“if the resolution of the conflict drags, that probably will be a headwind in some of these areas, particularly inflation trends as we get further into the second and the third quarter,” Solomon said. “So we’ll have to watch that.”
Solomon also said that market churn from the war cooled IPO listings in March, but that he still saw the need for several large IPOs in the pipeline to come to market.
-
Fashion7 days agoIndia’s exports face reset as EU links trade to carbon metrics: EY
-
Politics1 week agoTrump confirms rescue of airman whose F-15 was downed in Iran
-
Tech5 days agoAs the Strait of Hormuz Reopens, Global Shipping Will Take Months to Recover
-
Entertainment6 days agoQueen Elizabeth II emotional message for Archie, Lilibet sparks speculation
-
Tech6 days agoAzure customers up in arms over ‘full’ UK South region | Computer Weekly
-
Entertainment7 days agoLamar Odom shocking response to Khloé Kardashian account of his overdose
-
Sports1 week agoWith Messi goal, Inter Miami open new stadium with dream moment
-
Tech5 days agoThis AI Button Wearable From Ex-Apple Engineers Looks Like an iPod Shuffle
